RT Journal Article
SR Electronic
T1 Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3135
OP 3143
DO 10.21873/anticanres.16486
VO 43
IS 7
A1 SUZUKI, HIROTAKA
A1 URABE, FUMIHIKO
A1 IWATANI, KOSUKE
A1 MIYAJIMA, KEIICHIRO
A1 IMAI, YU
A1 TASHIRO, KOJIRO
A1 TSUZUKI, SHUNSUKE
A1 HONDA, MARIKO
A1 KOIKE, YUSUKE
A1 AOKI, MANABU
A1 SATO, SHUN
A1 TAKAHASHI, HIROYUKI
A1 MIKI, KENTA
A1 KIMURA, TAKAHIRO
YR 2023
UL http://ar.iiarjournals.org/content/43/7/3135.abstract
AB Background/Aim: A recent clinical trial indicated the usefulness of local radiation therapy of the prostate in patients with low-volume metastatic prostate cancer. High-dose-rate brachytherapy (HDR-BT) is used mainly for high-risk, localized, and locally advanced cases. However, few studies exist on the efficacy of HDR-BT and external beam radiation therapy (EBRT) for metastatic prostate cancer. Patients and Methods: We conducted a retrospective analysis of 39 patients diagnosed with regional lymph node metastasis and/or a limited number of metastases who underwent HDR-BT and EBRT with long-term androgen deprivation therapy. We utilized Cox’s proportional hazards models to identify predictors of oncological outcomes. Treatment outcomes, including biochemical recurrence-free survival (BCRFS), clinical progression-free survival (CPFS), and castration-resistant prostate cancer-free survival (CRPCFS), were compared according to the clinical stage. Results: The median follow-up duration was 49 months (range=23-136 months). The 5-year BCRFS, CPFS, CRPCFS, and cancer-specific survival rates were 62.2%, 67.2%, 83.2%, and 93.4%, respectively. Based on Kaplan–Meier analysis, N1M0 and N0-1M1b showed favorable outcomes compared with N1M1a. Multivariate analysis revealed that N1M1a prostate cancer was an independent risk factor for poor BCRFS, CPFS, and CRPCFS. Conclusion: HDR-BT and EBRT with androgen deprivation therapy is a feasible approach for patients with newly diagnosed regional and low-metastatic-burden prostate cancer. However, in our cohort M1a prostate cancer had significantly inferior outcomes. A well-controlled prospective study is imperative to confirm our results.